Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms

Overview

Service members and/or recently separated veterans with post traumatic stress symptoms and mild traumatic brain injury may participate in 8 sessions including 2 sessions including interviews and questionnaires as well as 6 sessions of art therapy. In the art therapy, participants will be provided with a blank paper mache mask template and invited to alter the mask however they wish using a variety of art materials. The therapist will use the art-making process and culminating product to aid in self-reflection, reframe negative thoughts and feelings, and work through traumatic content. Prior to the session start participants will get set up with a mobile qEEG (worn like a hat and backpack). The qEEG will measure brain activity in a non-invasive way throughout the art therapy session to improve understanding of brain activity during the art therapy process.

Full Title of Study: “Evaluation of Quantitative EEG During Art Therapy in Service Members With Co-Morbid Traumatic Brain Injury & Posttraumatic Stress Symptoms”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2022

Detailed Description

This is a pilot, interventional clinical trial in which all 9 service members with comorbid PTSD and mTBI participate in 8 sessions (1 baseline session of interviews and questionnaires, 6 sessions of art therapy, and 1 final session of interviews and questionnaires). Participants must have significant posttraumatic stress symptoms and a history of mild traumatic brain injury. Target enrollment is 9 active duty service members or recently separated veterans, aged 18-64 with no prior art therapy exposure, at the NICoE at Walter Reed National Military Medical Center in Bethesda, MD. Background: Posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) are persistent and frequently comorbid complications of combat that remain a challenge to healthcare providers. In these complex cases, traditional treatments often fail to provide complete relief from symptoms associated with posttraumatic stress (PTS), anxiety, and depression, leading the military healthcare system to look towards complementary and integrative treatments. Art therapy is one promising intervention that helps service members (SMs) develop a "visual voice," using imagery, symbolism, and metaphor to externalize emotions and experiences that they may not be able to express in words. The standardized, integrative mental health and human services approach of the art therapy program at the NICoE utilizes a mask-making directive to explore thoughts, feelings, and experiences of combat and self-understanding. This process is especially relevant to SMs with PTS symptoms who often remember their trauma as an incoherent, fragmented memory that is often predominantly sensory in nature. NICoE researchers have provided preliminary evidence suggesting associations between recurring art themes represented within the masks and individual BH symptoms; yet, the neurobiological mechanisms underlying this therapeutic technique remain obscure. To date, there have been few studies using neuroimaging techniques to investigate brain network changes during art creation. Studies have utilized electroencephalography (EEG) and functional near infrared spectroscopy (fNIRS) during art creation but not within the context of art therapy. Mobile, quantitative EEG allows for real time data capture that could minimize interference of neuroimaging during the therapeutic process and provide insight into the neurological mechanisms underlying art therapy. Study design and procedures: Participants will be provided with a blank paper mache mask template and invited to alter the mask however they wish using a variety of art materials. The therapist will use the art-making process and culminating product to aid in self-reflection, reframe negative thoughts and feelings, and work through traumatic content. Prior to the session start participants will get set up with the mobile qEEG. The qEEG will be segmented into a pre-art therapy session resting state, prompt-specific tasks during the art therapy session, and a post-art therapy session resting state.

Interventions

  • Behavioral: Art Therapy
    • This is a pilot study in which every participant receives the art therapy intervention arm. There are no waitlist or control arms. Art therapy is one promising intervention that helps service members (SMs) develop a “visual voice,” using imagery, symbolism, and metaphor to externalize emotions and experiences that they may not be able to express in words. The standardized, integrative mental health and human services approach of the art therapy program at the NICoE utilizes a mask-making directive to explore thoughts, feelings, and experiences of combat and self-understanding. This process is especially relevant to SMs with PTS symptoms who often remember their trauma as an incoherent, fragmented memory that is often predominantly sensory in nature. NICoE researchers have provided preliminary evidence suggesting associations between recurring art themes represented within the masks and individual BH symptoms.

Arms, Groups and Cohorts

  • Other: qEEG Art Therapy
    • Participants will receive art therapy while a noninvasive, mobile qEEG measures brain activity. There is no comparison as this is an exploratory pilot study.

Clinical Trial Outcome Measures

Primary Measures

  • The primary outcome measure is an analysis of qEEG session data.
    • Time Frame: during the intervention Session 1 (Week 2)
    • The primary outcome measure is an analysis of qEEG session data, which will include regional and global power across the following frequency bands: delta (1-4 Hz), theta (4-7 Hz), alpha (8-13 Hz), beta (13- 30 Hz), and gamma (>30 Hz); global interhemispheric coherence; and regional coherence between pairs of sensor locations. Global/regional power (units: micro-Volts-squared per Hz (uV2/Hz) Interhemispheric coherence (units coherence) Regional coherence (units coherence)
  • The primary outcome measure is an analysis of qEEG session data.
    • Time Frame: during the intervention Session 2 (Week 3)
    • The primary outcome measure is an analysis of qEEG session data, which will include regional and global power across the following frequency bands: delta (1-4 Hz), theta (4-7 Hz), alpha (8-13 Hz), beta (13- 30 Hz), and gamma (>30 Hz); global interhemispheric coherence; and regional coherence between pairs of sensor locations. Global/regional power (units: micro-Volts-squared per Hz (uV2/Hz) Interhemispheric coherence (units coherence) Regional coherence (units coherence)
  • The primary outcome measure is an analysis of qEEG session data.
    • Time Frame: during the intervention Session 3 (Week 4)
    • The primary outcome measure is an analysis of qEEG session data, which will include regional and global power across the following frequency bands: delta (1-4 Hz), theta (4-7 Hz), alpha (8-13 Hz), beta (13- 30 Hz), and gamma (>30 Hz); global interhemispheric coherence; and regional coherence between pairs of sensor locations.Global/regional power (units: micro-Volts-squared per Hz (uV2/Hz) Interhemispheric coherence (units coherence) Regional coherence (units coherence)
  • The primary outcome measure is an analysis of qEEG session data.
    • Time Frame: during the intervention Session 4 (Week 5)
    • The primary outcome measure is an analysis of qEEG session data, which will include regional and global power across the following frequency bands: delta (1-4 Hz), theta (4-7 Hz), alpha (8-13 Hz), beta (13- 30 Hz), and gamma (>30 Hz); global interhemispheric coherence; and regional coherence between pairs of sensor locations. Global/regional power (units: micro-Volts-squared per Hz (uV2/Hz) Interhemispheric coherence (units coherence) Regional coherence (units coherence)
  • The primary outcome measure is an analysis of qEEG session data.
    • Time Frame: during the intervention Session 5 (Week 6)
    • The primary outcome measure is an analysis of qEEG session data, which will include regional and global power across the following frequency bands: delta (1-4 Hz), theta (4-7 Hz), alpha (8-13 Hz), beta (13- 30 Hz), and gamma (>30 Hz); global interhemispheric coherence; and regional coherence between pairs of sensor locations. Global/regional power (units: micro-Volts-squared per Hz (uV2/Hz) Interhemispheric coherence (units coherence) Regional coherence (units coherence)
  • The primary outcome measure is an analysis of qEEG session data.
    • Time Frame: during the intervention Session 6 (Week 7)
    • The primary outcome measure is an analysis of qEEG session data, which will include regional and global power across the following frequency bands: delta (1-4 Hz), theta (4-7 Hz), alpha (8-13 Hz), beta (13- 30 Hz), and gamma (>30 Hz); global interhemispheric coherence; and regional coherence between pairs of sensor locations. Global/regional power (units: micro-Volts-squared per Hz (uV2/Hz) Interhemispheric coherence (units coherence) Regional coherence (units coherence)

Secondary Measures

  • CAPS-5
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • Clinician-Administered PTSD Scale for DSM-5
  • TAS-20
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • The Toronto Alexithymia Scale
  • AIQ
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • Aspects of Identity Questionnaire
  • PCL-5
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • Post Traumatic Stress Symptom Questionnaire
  • GAD-7
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • General Anxiety Disorder Questionnaire
  • PHQ-9
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • Patient Health Questionnaire for depression symptoms
  • PHQ-15
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • Patient Health Questionnaire for somatic symptoms
  • NSI
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • Neurological Symptom Inventory
  • PGIC
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • General Impression of Change
  • SUD Scores
    • Time Frame: baseline (pre-intervention) and immediately after the intervention; within a period of 8 weeks
    • Subjective Units of Distress

Participating in This Clinical Trial

Inclusion Criteria

  • Active duty service member or recently separated veteran (within the past 5 years) – DEERs eligible – Significant posttraumatic stress symptoms – History of mild traumatic brain injury – Aged 18-64 Exclusion Criteria:

  • Previous art therapy exposure – Moderate, severe, or penetrating TBI history – History of a psychotic disorder, bipolar disorder, or active suicidal or homicidal ideation – Unable to provide informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Walter Reed National Military Medical Center
  • Collaborator
    • National Intrepid Center of Excellence
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Chandler Rhodes, 3012755762, dha.bethesda.j-11.mbx.nicoe-research-studies@mail.mil

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.